E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
The hypothesis is that 99mTc-tilmanocept (Lymphoseek®) can be used safely and will be comparable to nanocolloidal human serum nanocolloidal albumin in Head and Neck, Melanoma and Breast Cancer sentinel lymph node detection and mapping. |
La hipótesis es que 99mTc-tilmanocept (Lymphoseek®) se puede usar de forma segura y será comparable a la albúmina nanocoloidal de suero humano nanocoloidal en la detección y mapeo de ganglios linfáticos centinela de cabeza y cuello, melanoma y cáncer de mama. |
|
E.1.1.1 | Medical condition in easily understood language |
Comparison of the concordance of albumin nanocolloid and Lymphoseek® in the detection of lymph nodes of primary and secondary stage drainage by performing two lymphogammagrams |
Comparación de la concordancia de Albumina nanocolloide y Lymphoseek® en la detección de ganglios linfáticos de drenaje primario y escalón secundario mediante la realización de dos linfogammagrafías |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Nodal Concordance defined as the proportion of lymph nodes identified by 99mTc-tilmanocept (Lymphoseek®) compared to the number of lymph nodes identified by nanocolloidal human serum albumin (Nanocolloid®) by performing two separate pre-operative lymphoscintigraphies [Washout period: 2 Day] |
Comparación de la concordancia de Nanocoll® y Lymphoseek® en la detección de ganglios linfáticos de drenaje primario y escalón secundario mediante la realización de dos linfogammagrafías con estudio dinámico estandarizado que incluye imágenes planares precoces y tardías y tomografía SPECT/CT. |
|
E.2.2 | Secondary objectives of the trial |
Time frame to ascertain the sentinel nodes Concordance among early and delayed images obtained with Lymphoseek® Number of sentinel nodes and secondary nodes depicted Tracer retention in injection site Safety and tolerability of 99mTctilmanocept (Lymphoseek®) |
• Número de ganglios linfáticos por paciente detectados con cada radiotrazador mediante imágenes de SPECT/CT. • Tiempo de detección de ganglios centinela y en la distribución de los trazadores entre las imágenes precoces y tardías. (El tiempo de localización del ganglio centinela se evaluará mediante linfogammagrafía por la imposibilidad de evaluar estos tiempos de manera intraoperatoria). • Diferencia en el número de ganglios centinela y de segundo escalón detectados por paciente detectados mediante Lymphoseek® y Nanocoll® y las imágenes de SPECT/CT. • Frecuencia de aparición de contecimientos adversos |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Written informed consent Histologically confirmed diagnosis of melanoma, breast cancer or head and neck cancer and candidate for surgical resection with lymph node mapping being a part of the surgical plan. At least 18 years of age at the time of consent. The subject is clinically node negative (cN0) at the time of screening. In Melanoma Patients - Diagnosis of primary melanoma with sentinel node indication ( >0.8 mm Breslow thickness; clinically negative lymph nodes) In Breast Cancer Patients - T1-T2 N0 breast cancer. - Patients with pure ductal carcinoma in situ (DCIS) if lymph node biopsy is part of the surgical plan. In Oral cavity tumors patients - T1-T2 N0 oral cavity squamous cell carcinoma |
• Pacientes con diagnóstico de melanoma, de cáncer de mama o de cabeza y cuello confirmado histológicamente y candidato a resección quirúrgica con mapeo de ganglios linfáticos e identificación de ganglio centinela como parte del plan quirúrgico. • Edad de 18 años o superior en el momento de otorgar el consentimiento.. • Sujetos clínicamente con nódulos negativos (cN0) en el momento del screening. • Pacientes con melanoma (de línea media, troncal o cabeza y cuello) - Diagnóstico de melanoma primario con indicación de ganglio centinela ( grosor >0.8 mm Breslow; nódulos linfáticos clínicamente negativos) • Pacientes con cancer de mama (mujeres con IMC > 30 o edad > 65 o que han recibido cirugía o quimioterapia previas) - Cáncer de mama T1-T2 N0. Pacientes con carcinoma ductal in situ (DCIS) puro si la biopsia de ganglios linfáticos es parte del plan quirúrgico). • Pacientes con tumores de cavidad oral (especialmente suelo de boca o línea media) - Carcinoma de células escamosas de cavidad oral T1-T2 N0 |
|
E.4 | Principal exclusion criteria |
Pregnancy or lactation Clinical or radiological evidence of metastatic cancer including palpably abnormal or enlarged lymph nodes Patients that have had preoperative chemotherapy, immunotherapy or radiation therapy Patients who have undergone node basin surgery of any type or radiation to the nodal basin(s) potentially draining the primary tumor Patients who have undergone a wide excision for their tumor or complex reconstruction (rotation, free flap or skin graft of any type). |
• Mujeres embarazadas o en periodo de lactancia • Evidencia clínica o radiológica de metástasis ganglionares (incluidos ganglios palpables anormales o aumentados de tamaño) • Pacientes que han recibido radioterapia preoperatoria • Pacientes sometidos a cirugía o radioterapia de la Cuenca linfática donde drena el tumor primario • Pacientes que han sido sometidos a escisión quirúrgica amplia del tumor o reconstrucción compleja (rotación, colgajo libre o injerto de cualquier tipo). |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Assessment of the concordance of albumin nanocolloid and Lymphoseek® in lymphatic drainage including the detection of both, primary and secondary lymph nodes, by means of a limphoscintigraphy with standardized dynamic study which includes early and delayed images and an SPECT/CT. |
Evaluación de la concordancia de nanocoloide de albúmina y Lymphoseek® en el drenaje linfático, incluida la detección de ganglios linfáticos primarios y secundarios, mediante una limfogammagrafía con estudio dinámico estandarizado que incluye imágenes tempranas y tardías y una SPECT / CT. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
30-60 minutes |
30-60 minutos |
|
E.5.2 | Secondary end point(s) |
Secondary Efficacy endpoints:
Per subject concordance of the lymphatic node stations detected with both radiotracers and the SPECT/CT images. Per subject concordance of the timeframe to ascertain sentinel nodes. Time to localization of the sentinel node would be assessed by limphoscintigraphy due to the impossibility to asses both times intraoperatively. Per subject concordance in the number of sentinel nodes detected and secondary nodes depicted among Lymphoseek® and albumianocolloid and the SPECT/CT images. Concordance among early and delayed images obtained with Lymphoseek® and the SPECT/CT
Other secondary endpoints
Adverse events [Timeframe 7 days]. |
Puntos finales de eficacia secundaria:
Concordancia por sujeto de las estaciones de ganglios linfáticos detectadas con radiotrazadores y las imágenes SPECT / CT. Concordancia por sujeto del plazo para determinar los ganglios centinela. El tiempo hasta la localización del ganglio centinela se evaluaría mediante limfogammagrafía debido a la imposibilidad de evaluar ambas veces durante la operación. Concordancia por sujeto en el número de ganglios centinelas detectados y ganglios secundarios representados entre Lymphoseek® y albumianocoloide y las imágenes SPECT / CT. Concordancia entre imágenes tempranas y tardías obtenidas con Lymphoseek® y SPECT / CT
Otros puntos finales secundarios
Eventos adversos [Marco de tiempo 7 días]. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
30-60 minutes |
30-60 minutos |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS |
Última visita del último paciente |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |